[
  {
    "ts": null,
    "headline": "This Overlooked Biotech Giant Could Surprise Investors This Quarter",
    "summary": "Investors may be underestimating the long-term potential of Gilead’s evolving portfolio.",
    "url": "https://finnhub.io/api/news?id=8a356ceb4269a69fedb465167eeb1e6636d68756deaf301ed1a6573d39d8bd54",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770321940,
      "headline": "This Overlooked Biotech Giant Could Surprise Investors This Quarter",
      "id": 138369841,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Investors may be underestimating the long-term potential of Gilead’s evolving portfolio.",
      "url": "https://finnhub.io/api/news?id=8a356ceb4269a69fedb465167eeb1e6636d68756deaf301ed1a6573d39d8bd54"
    }
  },
  {
    "ts": null,
    "headline": "Is Gilead Sciences (GILD) Still Attractive After Strong Multi‑Year Share Price Gains",
    "summary": "If you are wondering whether Gilead Sciences stock still offers value at current levels, it helps to start with what the recent share price is signalling and how that lines up with fundamentals. Gilead Sciences shares most recently closed at US$146.23, with returns of 4.7% over 7 days, 23.6% over 30 days, 20.3% year to date, 50.8% over 1 year, 89.7% over 3 years, and 163.3% over 5 years. This gives useful context before comparing the price to any estimate of fair value. Recent news around...",
    "url": "https://finnhub.io/api/news?id=73a133270cd9f58e8691b930fd2e5a674fa2d6f0bd271af5a1db3786e34777c4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770315014,
      "headline": "Is Gilead Sciences (GILD) Still Attractive After Strong Multi‑Year Share Price Gains",
      "id": 138367569,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "If you are wondering whether Gilead Sciences stock still offers value at current levels, it helps to start with what the recent share price is signalling and how that lines up with fundamentals. Gilead Sciences shares most recently closed at US$146.23, with returns of 4.7% over 7 days, 23.6% over 30 days, 20.3% year to date, 50.8% over 1 year, 89.7% over 3 years, and 163.3% over 5 years. This gives useful context before comparing the price to any estimate of fair value. Recent news around...",
      "url": "https://finnhub.io/api/news?id=73a133270cd9f58e8691b930fd2e5a674fa2d6f0bd271af5a1db3786e34777c4"
    }
  },
  {
    "ts": null,
    "headline": "White House launches direct-to-consumer drug site TrumpRx. Here's what to know",
    "summary": "It's still unclear if all patients, particularly those with insurance coverage, will see more cost savings from using that site to buy their medicines.",
    "url": "https://finnhub.io/api/news?id=2bd365464a64554c833510a14890e7731969ce8b179362b23305539a1ee9b7eb",
    "source": "CNBC",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770305054,
      "headline": "White House launches direct-to-consumer drug site TrumpRx. Here's what to know",
      "id": 138376237,
      "image": "https://image.cnbcfm.com/api/v1/image/108262460-1770383887859-gettyimages-2259525568-TRUMPRX_LAUNCH.jpeg?v=1770384067&w=1920&h=1080",
      "related": "GILD",
      "source": "CNBC",
      "summary": "It's still unclear if all patients, particularly those with insurance coverage, will see more cost savings from using that site to buy their medicines. ",
      "url": "https://finnhub.io/api/news?id=2bd365464a64554c833510a14890e7731969ce8b179362b23305539a1ee9b7eb"
    }
  },
  {
    "ts": null,
    "headline": "Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?",
    "summary": "Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=865ff228e6e365245401575aabee9d15f76755d5b9ded17851cf79b29902b93b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770303606,
      "headline": "Agios Pharmaceuticals (AGIO) Expected to Beat Earnings Estimates: Can the Stock Move Higher?",
      "id": 138366165,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Agios Pharmaceuticals (AGIO) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=865ff228e6e365245401575aabee9d15f76755d5b9ded17851cf79b29902b93b"
    }
  },
  {
    "ts": null,
    "headline": "Ahead of Gilead (GILD) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics",
    "summary": "Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.",
    "url": "https://finnhub.io/api/news?id=b0dce09482edd946df009c19f0823f3fe644da6f3daaf891e16a84c659fa518a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770300906,
      "headline": "Ahead of Gilead (GILD) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics",
      "id": 138364535,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended December 2025.",
      "url": "https://finnhub.io/api/news?id=b0dce09482edd946df009c19f0823f3fe644da6f3daaf891e16a84c659fa518a"
    }
  },
  {
    "ts": null,
    "headline": "Should You Buy, Hold, or Sell GILD Stock Ahead of Q4 Earnings?",
    "summary": "GILD readies Q4 results as HIV drugs Biktarvy and Descovy drive growth, while Yeztugo uptake and cell therapy headwinds shape expectations.",
    "url": "https://finnhub.io/api/news?id=64329d8ff9d20284c5cc2c4b877e09f0b7c4d9b8b97abb784b992b951a8d48ee",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770300900,
      "headline": "Should You Buy, Hold, or Sell GILD Stock Ahead of Q4 Earnings?",
      "id": 138366124,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "GILD readies Q4 results as HIV drugs Biktarvy and Descovy drive growth, while Yeztugo uptake and cell therapy headwinds shape expectations.",
      "url": "https://finnhub.io/api/news?id=64329d8ff9d20284c5cc2c4b877e09f0b7c4d9b8b97abb784b992b951a8d48ee"
    }
  },
  {
    "ts": null,
    "headline": "Cell and Gene Therapy in Numbers: $1.2B in Zolgensma Sales, $1.5B Yescarta Revenue, 46 FDA-Approved Therapies and $2B Strategic Deals",
    "summary": "This report provides an in-depth analysis of the Cell and Gene Therapy industry, highlighting key company revenues, regulatory approvals, and market trends. It has been compiled by Towards Healthcare, a sister firm of Precedence Research, offering valuable insights into the latest developments and financials in this rapidly advancing field.Ottawa, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cell and gene therapy (CGT) is rapidly advancing, with major players like Novartis, Gilead, and Bristol Myers Squibb",
    "url": "https://finnhub.io/api/news?id=7bd9f5e4b72b285309a575d0a27b7eb36934c64bb574d9a45dbb8f7700692882",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1770296400,
      "headline": "Cell and Gene Therapy in Numbers: $1.2B in Zolgensma Sales, $1.5B Yescarta Revenue, 46 FDA-Approved Therapies and $2B Strategic Deals",
      "id": 138363586,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "This report provides an in-depth analysis of the Cell and Gene Therapy industry, highlighting key company revenues, regulatory approvals, and market trends. It has been compiled by Towards Healthcare, a sister firm of Precedence Research, offering valuable insights into the latest developments and financials in this rapidly advancing field.Ottawa, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Cell and gene therapy (CGT) is rapidly advancing, with major players like Novartis, Gilead, and Bristol Myers Squibb",
      "url": "https://finnhub.io/api/news?id=7bd9f5e4b72b285309a575d0a27b7eb36934c64bb574d9a45dbb8f7700692882"
    }
  }
]